← Back to Search

Behavioral Intervention

Weight Management for Prostate Cancer (WARRIOR Trial)

N/A
Waitlist Available
Led By Jill Hamilton-Reeves, PhD
Research Sponsored by University of Kansas Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Men newly diagnosed with PCa who are scheduled for radical prostatectomy (RP) (T1 or T2)
Be older than 18 years old
Must not have
Undergoing salvage therapy
Castration-resistant PCa
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline to month 6
Awards & highlights

Summary

This trial aims to see how a weight management program affects certain substances in the blood that can indicate the presence or severity of cancer, compared to just following a basic diet and exercise plan.

Who is the study for?
This trial is for men newly diagnosed with prostate cancer (stages T1 or T2) who are overweight or obese, with a BMI between 25-45 kg/m2. Participants must be scheduled for radical prostatectomy and have internet access to join the study.
What is being tested?
The study is examining the effects of a weight management program on cancer biomarkers in blood versus just receiving an educational flyer about diet and exercise. It aims to see if managing weight can influence recovery from surgery and cancer outcomes.
What are the potential side effects?
Since this trial involves non-invasive interventions like education and weight management programs, side effects may include typical reactions to lifestyle changes such as muscle soreness, fatigue, or dietary adjustment discomfort.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a man newly diagnosed with prostate cancer and scheduled for complete prostate removal.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am receiving treatment after my cancer has not responded to initial treatments.
Select...
My prostate cancer is not responding to hormone therapy.
Select...
I have had radiation therapy for cancer.
Select...
I have a serious health condition like kidney disease or uncontrolled diabetes.
Select...
I am currently undergoing treatment for cancer.
Select...
My cancer has spread to other parts of my body.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline to month 6
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline to month 6 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Impact of weight loss before and weight maintenance after Prostate Cancer (PCa) surgery on immunosuppressive factors
Secondary study objectives
Change in Quality of Life
Change in body composition
Impact of weight loss before and weight maintenance after PCa surgery on inflammation factors

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Weight Loss and Weight MaintenanceExperimental Treatment2 Interventions
Participants will take part in a weight loss program for at least 4 weeks (and up to 16 weeks) before their prostatectomy, and a weight maintenance program for 6 months after their surgery.
Group II: ControlActive Control1 Intervention
Participants will receive a standardized educational flyer about a healthy diet and exercise.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Weight Loss Program
2006
N/A
~250

Find a Location

Who is running the clinical trial?

University of Kansas Medical CenterLead Sponsor
488 Previous Clinical Trials
172,415 Total Patients Enrolled
21 Trials studying Obesity
103,712 Patients Enrolled for Obesity
American Cancer Society, Inc.OTHER
226 Previous Clinical Trials
110,603 Total Patients Enrolled
3 Trials studying Obesity
537 Patients Enrolled for Obesity
Jill Hamilton-Reeves, PhDPrincipal InvestigatorUniversity of Kansas Medical Center
1 Previous Clinical Trials
20 Total Patients Enrolled
~5 spots leftby Sep 2025